Key findings from detailed records
Population: 67 pregnant women in Qatar; 43 followed through delivery. The planned sample was 640. Findings: No significant differences in incidence or maternal and neonatal outcomes. The authors judged the findings inconclusive because of insufficient power.
KNOWLEDGE RECORD
- Category
- Metabolism and cellular function
- Last Reviewed
Names and related search termsMyo-inositol / Myo-inositol
Study type: small exploratory studies.
OUTCOME-SPECIFIC EVIDENCE
Scientific Evidence Profile
Assessment pending
An outcome-specific assessment has not yet been completed. This is not a finding that the ingredient is ineffective. The study records below remain available.
This profile concerns the stated outcome and population, not the ingredient as a whole. It is not a probability of benefit, a safety rating, a product efficacy rating or an indication of product adoption.
How we assess evidenceIngredient Profile
- What is it?
- Myo-inositol is one stereochemical form of inositol, a cyclic sugar alcohol. Different arrangements of the same atoms can give rise to different forms of inositol. [1]
Sources for this profile
Compound properties and formulation properties are different. These sources do not establish the efficacy of a finished supplement.
- PubChem — An inositol (CID 892) Chemical identity reference. Maintained by NCBI, U.S. National Library of Medicine. Database record; not a clinical trial.
Profile sources checked:
Read the evidence in context
- Evidence: what was measured in the stated population or experimental model.
- Inference: an interpretation connecting findings; its applicability depends on the study conditions.
- Hypothesis: a proposed explanation or effect that remains to be tested.
Why It Matters #
Does finding no difference in a small trial establish no effect? Check the detailed records for study conditions and use the literature map to compare other populations and outcomes.
What Was Studied #
67 pregnant women in Qatar; 43 followed through delivery. The planned sample was 640. MiGDM: randomized, double-blind, placebo-controlled pilot trial. Outcomes: Incidence of gestational diabetes[1]
What Was Found #
No significant differences in incidence or maternal and neonatal outcomes. The authors judged the findings inconclusive because of insufficient power.[1]
What the Evidence Means #
Ended early because of funding constraints. Under-recruitment, attrition and baseline imbalances prevent firm conclusions for or against efficacy.[1]
Comparing similar populations, formulations, durations and outcomes helps identify where findings agree and where they differ.
What We Can Learn #
Do not transfer this pregnancy study to PCOS or general metabolic improvement. Do not begin use during pregnancy without professional advice.
What Remains Unknown #
Further questions include reproducibility across populations and formulations, and the long-term balance of benefits and harms. Use the literature map as a starting point for these questions.
LITERATURE MAP / 10 PAPERS
Compare papers by conditions and findings.
A literature map covering different populations, outcomes and formulations. Read alongside detailed records to avoid treating one trial as the conclusion for an entire ingredient.
Selected: 2026-09-21. Bibliographic information checked against Europe PMC / PubMed. Editorial selection considered major papers and a range of populations and questions. This is not a systematic search covering all recent research.
10 RECORDS
A dash marks fields outside the bibliographic record. Use detailed records to compare findings and design records to connect mechanisms.
No papers match. Change the search conditions.
The literature map is an index of research questions and references. Individual assessment of results, doses, funding and COI is limited to the detailed study records. Related reports from the same trial may be included; paper counts are not counts of independent trials.
Explore the research Study Records
Listed doses describe study conditions, not recommended intake.
The Effect of Myo-Inositol Supplementation During Pregnancy on Fetal and Maternal Outcomes: Results of the Myo-Inositol for the Prevention of Gestational Diabetes Mellitus (MiGDM) Randomized Double-Blind, Placebo-Controlled Pilot Trial.
PubMed 41742988DOI: 10.7759/cureus.102259
- Authors
- Okunoye G, George Samuel C, Abdullahi H, Terranegra A, Ibrahim IM.
- Journal
- Cureus
- Publication year
- 2026
- Study design
- MiGDM: randomized, double-blind, placebo-controlled pilot trial
- Participants
- 67 pregnant women in Qatar; 43 followed through delivery. The planned sample was 640.
- Dose and intervention
- 2 g twice daily
- Duration
- From before 16 weeks of pregnancy until delivery
- Outcomes and their role in the study
- Incidence of gestational diabetes
- Findings
- No significant differences in incidence or maternal and neonatal outcomes. The authors judged the findings inconclusive because of insufficient power.
- Limitations
- Ended early because of funding constraints. Under-recruitment, attrition and baseline imbalances prevent firm conclusions for or against efficacy.
- Funding
- The text describes early termination due to funding constraints, while the disclosure reports no financial support for this research. The relationship between these statements remains unresolved.
- Conflict of Interest
- The authors declared no relevant financial or other relationships.
- Scope of source review
- Bibliographic information and abstract checked, along with relevant funding and conflict-of-interest sections in the public full text. This is not a comprehensive critical appraisal of the full paper.
Cite this page
LÍFSVARÐA. Myo-inositol: Does finding no difference in a small trial establish no effect? Version 1.1 / Updated 2026-10-24
https://lifsvarda.com/knowledge/myo-inositol/Edited by LÍFSVARÐA (product brand).Editorial policy
Sources and updates
- Okunoye G, George Samuel C, Abdullahi H, Terranegra A, Ibrahim IM. (2026). The Effect of Myo-Inositol Supplementation During Pregnancy on Fetal and Maternal Outcomes: Results of the Myo-Inositol for the Prevention of Gestational Diabetes Mellitus (MiGDM) Randomized Double-Blind, Placebo-Controlled Pilot Trial.Bibliographic information and abstract checked, along with relevant funding and conflict-of-interest sections in the public full text. This is not a comprehensive critical appraisal of the full paper.
First published: 2026-09-21 / Version 1.1. Updated 2026-09-23: Added a research comparison table and links to design records. Source notes identify the scope of verification when the full paper has not been reviewed. Research summaries and LÍFSVARÐA’s interpretation are distinguished.